ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Market Cap	1.29B -72.4%
Revenue (ttm)	171.70M +108.1%
Net Income	-243.24M
EPS	-0.59
Shares Out	431.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	316,000
Open	2.930
Previous Close	2.920
Day's Range	2.930 - 3.150
52-Week Range	2.800 - 16.800
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About HKG:1541

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 202
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1541

Financial Performance

In 2025, HKG:1541's revenue was 154.29 million, an increase of 108.09% compared to the previous year's 74.15 million. Losses were -218.58 million, -30.80% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error